Avant Source™ automates the step that ensures sample reliability.

The instrument runs up to 12 cartridges at a time, one sample per cartridge, for meaningfully higher throughput per run without adding manual steps. Each cartridge accepts either EDTA or Streck tube samples.

Cartridges arrive pre-loaded with all necessary reagents and capture all process waste internally, making each one a fully self-contained, disposable consumable.

Each cartridge performs size-selective cfDNA enrichment and purification in a single enclosed, cartridge-based format, concentrating the tumor-derived fraction before it ever reaches sequencing.

At any given time, a blood sample contains DNA from three sources. Cell-free DNA (cfDNA) circulates naturally in the bloodstream after being released from healthy cells. Circulating tumor DNA (ctDNA) is a small subset of cfDNA shed by cancer cells that can provide valuable insights into disease. Genomic DNA (gDNA), released when blood cells are damaged, can contaminate the sample and overwhelm the much smaller cfDNA population, reducing sensitivity. Because ctDNA often represents less than 1% of total cfDNA, recovering as much cfDNA as possible while minimizing gDNA contamination is critical for accurate liquid biopsy testing. Avant Source performs automated cfDNA isolation and purification within a fully enclosed cartridge, maximizing recovery while minimizing variability and hands-on time.